LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Takeda Pharmaceutical Co Ltd ADR

Geschlossen

BrancheGesundheitswesen

14.96 -0.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

14.92

Max

15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-68B

24B

Verkäufe

-32B

1.1T

KGV

Branchendurchschnitt

65.565

51.198

EPS

0.048

Dividendenrendite

4.32

Gewinnspanne

2.08

EBITDA

-4.3B

380B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+6.74% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.32%

2.40%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

47B

Vorheriger Eröffnungskurs

15.03

Vorheriger Schlusskurs

14.96

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Takeda Pharmaceutical Co Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Mai 2025, 08:08 UTC

Ergebnisse

Takeda's Annual Net Profit Slumps on Expenses, Costs

9. Apr. 2025, 09:39 UTC

Wichtige Markttreiber

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

30. Jan. 2025, 11:02 UTC

Ergebnisse

Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO -- Update

30. Jan. 2025, 07:53 UTC

Ergebnisse

Takeda Pharmaceutical Raises Earnings Guidance, Names Julie Kim as New CEO

8. Mai 2025, 06:34 UTC

Ergebnisse

Takeda Pharmaceutical FY Net Profit Missed Y134.71B Expected in Poll of Analysts by Quick >4502.TO

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY EPS Y68.36 Vs EPS Y92.09

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY Net Y107.93B Vs Net Y144.07B

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Sees FY Net Y228.00B

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY Oper Pft Y342.59B Vs Pft Y214.08B

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY Rev Y4.58T Vs Y4.26T

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Raises FY Dividend to Y196.00

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY Pretax Pft Y175.08B Vs Pft Y52.79B

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical FY Net Y107.93B Vs Net Y144.07B

8. Mai 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Sees FY Net Y228.00B

30. Jan. 2025, 07:12 UTC

Ergebnisse

Correct: Takeda: U.S. Business Unit President Julie Kim to Become CEO in June 2026, Not June

30. Jan. 2025, 07:08 UTC

Ergebnisse

Takeda: U.S. Business Unit President Julie Kim to Become CEO in June

30. Jan. 2025, 06:42 UTC

Ergebnisse

Takeda 3Q Rev Y1.144T Vs. Y1.111T >4502.TO

30. Jan. 2025, 06:40 UTC

Ergebnisse

Takeda 3Q Net Y23.8B Vs. Net Y105.7B >4502.TO

30. Jan. 2025, 06:36 UTC

Ergebnisse

Takeda: to Discontinue Soticlestat Development Program

30. Jan. 2025, 06:34 UTC

Ergebnisse

Takeda: Program May Repurchase Up to 1.8% of Outstanding Shares

30. Jan. 2025, 06:32 UTC

Ergebnisse

Takeda: To Buy Back Up to Y100B of Own Shares from Feb. 17 to May 31

30. Jan. 2025, 06:31 UTC

Ergebnisse

Takeda Pharmaceutical Raises Revenue, Net-Profit Views for FY Ending March

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Sees FY Net Y118.00B

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical 9-Mos Net Y211.08B Vs Net Y147.09B

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Sees FY Net Y118.00B

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical Raises FY Dividend to Y196.00

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical 9-Mos EPS Y133.71 Vs EPS Y94.10

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical 9-Mos Pretax Pft Y282.38B Vs Pft Y100.31B

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical 9-Mos Oper Pft Y417.52B Vs Pft Y224.14B

30. Jan. 2025, 06:30 UTC

Ergebnisse

Takeda Pharmaceutical 9-Mos Rev Y3.53T Vs Y3.21T

Peer-Vergleich

Kursveränderung

Takeda Pharmaceutical Co Ltd ADR Prognose

Kursziel

By TipRanks

6.74% Vorteil

12-Monats-Prognose

Durchschnitt 16 USD  6.74%

Hoch 16 USD

Tief 16 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Takeda Pharmaceutical Co Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 15.16Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Strong Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.